2674
Four days after the initial injection of 3.6 mg of goserelin acetate, severe dyspnea developed due to worsening pleuritis carcinomatosa, which was considered as a flare-up.
 severe dyspnea: Effect; worsening pleuritis carcinomatosa: Effect; injection of 3.6 mg of goserelin acetate: Treatment; injection: Treatment.Route; 3.6 mg: Treatment.Dosage; goserelin acetate: Treatment.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 severe dyspnea: Effect; worsening pleuritis carcinomatosa: Effect; injection of 3.6 mg of goserelin acetate: Treatment; injection: Treatment.Route; 3.6 mg: Treatment.Dosage; goserelin acetate: Treatment.Drug